Literature DB >> 34268637

Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management.

Daria Frestad Bechsgaard1, Eva Prescott2.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide an overview of diagnostic and treatment considerations in patients with coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease (CAD). RECENT
FINDINGS: The prevalence of obstructive CAD in unselected patient populations referred for evaluation of angina is less than 10%. A significant proportion of patients with angina and no obstructive CAD have CMD, a condition associated with impaired cardiovascular prognosis. Non-invasive and invasive evaluation of coronary microvascular function is feasible and widely available, yet CMD is underdiagnosed and undertreated. A patient-tailored treatment approach guided by coronary microvascular testing shows promising results for patient-reported outcomes of symptom burden and quality of life. Coronary microvascular testing should be considered in angina patients with no obstructive CAD, before other causes of chest pain are explored. A patient-tailored treatment approach guided by a complete evaluation of epicardial anatomy and macro-and microvascular function may help optimize treatment strategy and prevent unnecessary medical interventions. More research is needed to establish the long-term effect of patient-tailored therapies on risk reduction in CMD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Coronary artery disease; Coronary microvascular dysfunction; INOCA; Management; Microvascular angina; Stable angina pectoris

Year:  2021        PMID: 34268637     DOI: 10.1007/s11883-021-00947-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  62 in total

Review 1.  The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: A systematic review and meta-analysis.

Authors:  Philip Brainin; Daria Frestad; Eva Prescott
Journal:  Int J Cardiol       Date:  2018-01-28       Impact factor: 4.164

2.  Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.

Authors:  Carl J Pepine; R David Anderson; Barry L Sharaf; Steven E Reis; Karen M Smith; Eileen M Handberg; B Delia Johnson; George Sopko; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

3.  Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.

Authors:  Lasse Jespersen; Anders Hvelplund; Steen Z Abildstrøm; Frants Pedersen; Søren Galatius; Jan K Madsen; Erik Jørgensen; Henning Kelbæk; Eva Prescott
Journal:  Eur Heart J       Date:  2011-09-11       Impact factor: 29.983

4.  Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis.

Authors:  Francesco Radico; Marco Zimarino; Fabio Fulgenzi; Fabrizio Ricci; Marta Di Nicola; Lasse Jespersen; Su Min Chang; Karin H Humphries; Mario Marzilli; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2018-06-14       Impact factor: 29.983

5.  An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

Authors:  Vijay Kunadian; Alaide Chieffo; Paolo G Camici; Colin Berry; Javier Escaned; Angela H E M Maas; Eva Prescott; Nicole Karam; Yolande Appelman; Chiara Fraccaro; Gill Louise Buchanan; Stephane Manzo-Silberman; Rasha Al-Lamee; Evelyn Regar; Alexandra Lansky; J Dawn Abbott; Lina Badimon; Dirk J Duncker; Roxana Mehran; Davide Capodanno; Andreas Baumbach
Journal:  Eur Heart J       Date:  2020-10-01       Impact factor: 29.983

6.  Symptoms of angina pectoris increase the probability of disability pension and premature exit from the workforce even in the absence of obstructive coronary artery disease.

Authors:  Lasse Jespersen; Steen Z Abildstrøm; Anders Hvelplund; Søren Galatius; Jan K Madsen; Frants Pedersen; Søren Højberg; Eva Prescott
Journal:  Eur Heart J       Date:  2013-09-26       Impact factor: 29.983

7.  Low diagnostic yield of elective coronary angiography.

Authors:  Manesh R Patel; Eric D Peterson; David Dai; J Matthew Brennan; Rita F Redberg; H Vernon Anderson; Ralph G Brindis; Pamela S Douglas
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

8.  The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Kevin E Kip; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Gerald M Pohost; George Sopko
Journal:  Circulation       Date:  2006-08-21       Impact factor: 29.690

9.  Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study.

Authors:  Jakob Schroder; Marie M Michelsen; Naja D Mygind; Hannah E Suhrs; Kira B Bove; Daria Frestad Bechsgaard; Ahmed Aziz; Ida Gustafsson; Jens Kastrup; Eva Prescott
Journal:  Eur Heart J       Date:  2021-01-20       Impact factor: 29.983

10.  Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris.

Authors:  Lasse Jespersen; Steen Z Abildstrøm; Anders Hvelplund; Eva Prescott
Journal:  Clin Res Cardiol       Date:  2013-05-01       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.